secwatch.observer — SEC 8-K summary
======================================

Issuer:     Decoy Therapeutics Inc. (DCOY)
CIK:        0001615219
Form:       8-K
Filed at:   2025-08-27T23:59:59+00:00
Accession:  0001615219-25-000119
Event type: regulatory
Sentiment:  negative
Materiality: 0.90
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud

Salarius Pharmaceuticals receives Nasdaq extension to regain equity compliance by Oct 20, 2025
--------------------------------------------------------------------------------

- Nasdaq Hearings Panel granted Salarius until October 20, 2025 to comply with the Equity Standard (Rule 5550(b)(1)).
- Salarius effected a 1-for-15 reverse stock split on August 15, 2025, targeting compliance with the $1.00 Minimum Bid Price by August 29, 2025.
- Previously received a Delisting Notice on April 23, 2025 for noncompliance with the Minimum Bid Price Requirement.
- The extension follows prior milestones, including a previous extension granted on July 28, 2025 for compliance by August 12 (equity) and August 29 (bid price).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1615219/000161521925000119/0001615219-25-000119-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1615219/000161521925000119/flks-20250827.htm
  HTML page:      https://secwatch.observer/filing/0001615219-25-000119

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer